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Abstract
Background—Spontaneous preterm birth (SPTB) remains a leading cause of neonatal morbidity 
and mortality amongst non-anomalous neonates in the United States. SPTB tends to recur at 
similar gestational ages. Intramuscular 17-alpha hydroxyprogesterone caproate (17OHP-C) 
reduces the risk of recurrent SPTB. Unfortunately, one-third of high-risk women will have a 
recurrent SPTB despite 17OHP-C therapy; the reasons for this variability in response are 
unknown.
Objective—We hypothesized that clinical factors among women treated with 17OHP-C who 
suffer recurrent SPTB at a similar gestational age differ from women who deliver later, that these 
associations could be used to generate a clinical scoring system to predict 17OHP-C response.
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Study Design—Secondary analysis of a prospective, multi-center, randomized controlled trial 
enrolling women with ≥1 prior singleton SPTB <37 weeks gestation. Participants received daily 
omega-3 supplementation or placebo for recurrent PTB prevention; all were provided 17OHP-C. 
Women were classified as a 17OHP-C responder or non-responder by calculating the difference in 
delivery gestational age between the 17OHP-C treated pregnancy and her earliest prior SPTB. 
Responders were women with pregnancy extending ≥3 weeks later compared to the delivery 
gestational age of their earliest prior PTB; non-responders delivered earlier or within 3 weeks of 
the gestational age of their earliest prior PTB. A risk score for non-response to 17OHP-C was 
generated from regression models using clinical predictors, and was validated in an independent 
population. Data were analyzed with multivariable logistic regression.
Results—754 women met inclusion criteria; 159 (21%) were non-responders. Responders 
delivered later on average (37.7 +/− 2.5 weeks) than non-responders (31.5 +/− 5.3 weeks), 
p<0.001. Among responders, 27% had a recurrent SPTB (vs. 100% of non-responders). 
Demographic characteristics were similar between responders and non-responders. In a 
multivariable logistic regression model, independent risk factors for non-response to 17OHP-C 
were each additional week of gestation of the earliest prior PTB (OR 1.23, 95% CI 1.17–1.30, 
p<0.001), placental abruption or significant vaginal bleeding (OR 5.60, 95% CI 2.46–12.71, 
p<0.001), gonorrhea and/or chlamydia in the current pregnancy (OR 3.59, 95% CI 1.36–9.48, 
p=0.010), carriage of a male fetus (OR 1.51, 95% CI 1.02–2.24, p=0.040), and a penultimate PTB 
(OR 2.10, 95% CI 1.03–4.25, p=0.041). These clinical factors were used to generate a risk score 
for non-response to 17OHP-C as follows: Black +1, male fetus +1, penultimate PTB +2, 
gonorrhea/chlamydia +4, placental abruption +5, earliest prior PTB was 32–36 weeks +5. A total 
risk score >6 was 78% sensitive and 60% specific for predicting non-response to 17OHP-C 
(AUC=0.69). This scoring system was validated in an independent population of 287 women; in 
the validation set, a total risk score >6 performed similarly with a 65% sensitivity, 67% specificity 
and AUC of 0.66.
Conclusions—Several clinical characteristics define women at risk for recurrent PTB at a 
similar gestational age despite 17OHP-C therapy, and can be used to generate a clinical risk 
predictor score. These data should be refined and confirmed in other cohorts, and women at high 
risk for non-response should be targets for novel therapeutic intervention studies.
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Introduction
The proportion of babies born preterm in the United States remains unacceptably high at 
11.4% (2013).1 The majority of preterm deliveries are spontaneous PTB (SPTB); this 
encompasses deliveries due to preterm premature rupture of membranes (PPROM), cervical 
insufficiency, and idiopathic preterm labor.2 A history of a prior SPTB is the biggest risk 
factor for preterm birth; SPTB recurs in 35–50% of women, and tends to recur at similar 
gestational ages.3–5 The probability of SPTB also increases with the number of prior SPTB a 
woman has experienced, with the most recent birth being the most predictive.4,6
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In 2003, Meis, et al. published results from a multicenter randomized controlled trial of 
intramuscular 17-alpha hydroxyprogesterone caproate (17-OHPC), demonstrating that 
weekly intramuscular injections beginning at 16–20 weeks gestation reduces the risk of 
recurrent prematurity by approximately one-third.7 Unfortunately, prophylactic 17OHP-C is 
not effective for all women, as one-third of high-risk women will have a recurrent PTB 
despite appropriate prophylaxis with 17OHPC; the reasons for this variable responsiveness 
are unknown. Limited genetic studies have found associations between genetic variation in 
the progesterone receptor and nitric oxide genes and clinical response to 17OHP-C.8,9 Other 
studies have focused on clinical factors in attempts to define the population of women most 
likely to respond to treatment, finding that those with a family history of PTB and those who 
experienced bleeding or abruption in the current pregnancy were less likely to respond to 17-
OHPC, and those who had a prior spontaneous PTB <34 weeks were more likely to deliver 
at term with 17-OHPC.10,11
We sought to compare demographic, historical, and antenatal factors between women who 
delivered at similar gestational age with 17OHP-C for recurrent spontaneous preterm birth 
(SPTB) prevention versus those women who deliver later with 17OHP-C.
Materials and Methods
This is a secondary analysis of a multicenter randomized controlled trial of daily omega-3 
supplementation versus placebo for recurrent preterm birth prevention conducted by the 
Eunice Kennedy Shriver National Institute for Child Health and Human Development 
Maternal Fetal Medicine Units Network.12 Briefly, women pregnant with a singleton, non-
anomalous fetus who had a history of a prior documented singleton SPTB between 20 weeks 
0 days gestation and 36 weeks 6 days gestation were recruited between 16 and 22 weeks 
gestation across thirteen clinical sites between January 2005 and October 2006. All 
participants received weekly 17OHP-C (beginning at randomization) as a part of the study, 
and were randomized to receive either a daily supplement of 1,200 mg of eicosapentaenoic 
acid (EPA, 20:5n-3) and 800mg docosahexaenoic acid (DHA, 22:6n-3), for a total of 2,000 
mg of omega-3 long chain polyunsaturated fatty acids (omega-3 group), divided into four 
capsules, or matching placebo capsules. The 17OHP-C injections were supplied by a 
company that manages investigational drugs (Eminent Services, Frederick, MD), and were 
continued until delivery or 36 weeks 6/7 days of gestation, whichever occurred first. 
Compliance with 17OHP-C injections was calculated as the number received divided by the 
expected number. Obstetric management was otherwise performed per each woman’s 
primary obstetric provider. The main study did not find any impact on the rate of PTB prior 
to 37, 35, or 32 weeks with omega-3 supplementation among women already receiving 
17OHP-C.12 Comprehensive obstetric history, longitudinal antenatal data, and detailed 
delivery information were collected at the time the main study was conducted.
Participants in the original study had the option of providing a maternal peripheral blood 
DNA sample, for a planned analysis of the relationship between maternal genotype at the –
308 position of the TNF-α gene, the –174 position of the IL-6 gene, and the +3954 position 
of the IL-1β gene and length of gestation and risk of extreme preterm delivery. The 
procedure for DNA extraction and sample genotyping was performed in accordance with 
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standard methodology.13 The authors found that women homozygous for the minor allele 
(A) at the –308 position in the promoter region of the TNF-α gene had a significantly 
shorter length of gestation.13
This secondary analysis used a de-identified data set, and after review by the Institutional 
Review Board at the University of North Carolina, was considered exempt from IRB 
oversight.
For this analysis, we included all women who had a documented earliest gestational age of 
prior PTB and with gestational age outcome information available in the current pregnancy. 
Gestational age was determined by a combination of last menstrual period (if available) and 
ultrasound.14 We excluded women who received fewer than 50% of expected 17OHP-C 
injections, regardless of delivery gestational age.
We classified women as a 17OHP-C responder or non-responder by calculating the 
difference in the gestational age at delivery between the 17OHP-C treated pregnancy and her 
earliest SPTB, as we have previously described.8,10 To review, the difference between the 
earliest delivery gestational age and the delivery gestational age with 17OHP-C was 
calculated, and termed the ‘17OHP-C effect.’ Women with a 17OHP-C effect of ≥3 weeks 
(i.e., the individual’s pregnancy or pregnancies treated with 17OHP-C delivered at least 3 
weeks later compared to the gestational age of the earliest PTB without 17OHP-C treatment) 
were considered 17OHP-C responders; this designation was made in part by using data 
originally published by Bloom, et al which showed that 70% of women with recurrent PTB 
will experience recurrence within 2 weeks of their initial PTB.15 Women with a negative 
overall 17OHP-C effect and those with an overall 17OHP-C effect of <3 weeks were 
classified as non-responders. Women with a 17OHP-C effect of <3 weeks but delivering at 
term (for example, if the earliest prior SPTB was at 35 weeks, and the patient delivered at 37 
weeks during the 17OHP-C treated pregnancy) were considered ‘equivocal’ 17OHP-C 
responders and were excluded from analysis. A separate limited subgroup analysis 
examining the subset of non-responders who delivered significantly earlier (≤3 weeks 
earlier) during the 17OHP-C treated pregnancy was also performed (‘possible harm’) group.
Bivariate analyses were conducted to compare 17OHP-C responders to non-responders 
using t-test, chi-square, or Fisher’s exact test, as appropriate. Genotype data were assessed 
using the additive model of inheritance (each copy of the minor allele was hypothesized to 
confer additional risk), and in the bivariate analysis, were analyzed separately by self- 
reported race/ethnicity group to reduce the chance of analytic error due to population 
stratification. Multivariable logistic regression analysis was performed to identify factors 
associated with non-response to 17OHP-C, using backwards variable selection, retaining all 
factors with p<0.20 in the final model.
Finally, a clinical prognostic score was developed. We used the final multivariable model as 
described in the methods above, and then retained only factors readily available during the 
antenatal period (e.g., we excluded genotype information and any data only available 
postnatally). A score was then derived for each prognostic variable using odds ratio 
estimates; each odds ratio coefficient was divided by the smallest odds ratio coefficient and 
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rounded up to the nearest 0.5 to produce a weighted score. Each woman was then assigned a 
risk score using this calculation, and the value of this score in predicting non-response to 
17P was then assessed. A statistical ‘cut-point’ was determined based on the risk score 
where the sensitivity and specificity were maximized, using the Liu method.16 The model 
was then validated using de-identified data from the randomized trial of 17OHP-C vs. 
placebo conducted by the Eunice Kennedy Shriver National Institute for Child Health and 
Human Development Maternal Fetal Medicine Units Network.7
All statistical analyses were performed using STATA version 13.1 (College Station, TX). For 
modeling, fewer than 5% of data were missing, so missing data were imputed by replacing 
missing values with the median for continuous variables and with the most frequent category 
for categorical variables, which works as well as multiple imputation with this small 
proportion of missing data.17 A p-value of <0.05 was considered statistically significant.
Results
From the original cohort of 852 women enrolled in the omega-3 RCT, 754 met inclusion 
criteria (Figure 1). Of note, 57/852 (6.7%) women from the original cohort had a 17OHP-C 
effect <3 weeks yet delivered at term because their earliest prior PTB was more than 34 
weeks gestation; these women were considered ‘equivocal’ responders and were excluded 
(Figure 1). Of the remaining women, 595/754 (78.9%) delivered at least 3 weeks later 
compared to the delivery gestational age of their previous earliest PTB and were considered 
17OHP-C responders, and 159 (21.1%) had a 17OHP-C effect <3 and were considered non-
responders. Of the 159 non-responders, 31 (19.4%) delivered ≥3 weeks earlier with 17OHP-
C. On average, responders delivered later (37.7 +/− 2.5 weeks) than non-responders (31.5 +/
− 5.3 weeks), p<0.001. Overall, 160/595 responders (26.9%) had a recurrent SPTB, but they 
were considered responders because they delivered ≥3 weeks later compared to their earliest 
SPTB.
Many demographic characteristics were similar between responders and non-responders, 
although non-responders were more likely to be White, and less likely to be of Hispanic 
ethnicity (Table 1). The gestational age of the earliest prior SPTB was later among non-
responders (32.3 ± 4.1 vs. 29.1 ± 4,5, p<0.001), but both groups had a similar number of 
prior SPTB (1.4 ± 0.6 vs. 1.4 ± 0.7, p=0.597), similar chance of having had multiple SPTB 
(34.6% vs. 28.4%, p=0.129), and similar proportion had one or more previous term 
deliveries (28.9% vs. 35.3%, p=0.132). The majority of women had a penultimate pregnancy 
delivering preterm; this did not vary by responder status (92.3% vs. 87.8%, p=0.121, Table 
1).
Several current pregnancy factors were also similar between 17OHP-C responders and non-
responders. However, non-responders were more likely to experience clinically significant 
vaginal bleeding or be diagnosed with a placental abruption in the current gestation (11.3% 
vs. 3.2%, p<0.001), and were also more likely to be diagnosed with gonorrhea and/or 
chlamydia during pregnancy (6.9% vs. 2.2%, p=0.003, Table 2). As expected, due to the 
higher rate of PTB among non-responders, this group was also more likely to receive 
antenatal corticosteroids (27.0% vs. 28.5%, p=0.017), tocolysis (32.7% vs. 18.0%, p<0.001), 
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and be admitted to the hospital for tocolysis or preterm labor symptoms (Table 2). Non-
responders were also more likely to carry a male fetus (57.9% vs. 47.9%, p=0.026, Table 2).
Next, we evaluated the relationship between the three maternal genotypes and 17OHP-C 
response (Tables 3 and 4). For both Black women and White/Hispanic women, there was a 
trend towards a relationship between maternal IL-1β+3954 genotype and 17OHP-C 
response, but this did not reach statistical significance (Tables 3 and 4).
In regression models, each additional week of gestation of the earliest prior SPTB (OR 1.23, 
95% CI 1.17–1.30, p<0.001), placental abruption or significant vaginal bleeding in the 
current pregnancy (OR 5.60, 95% CI 2.46–12.71, p<0.001), diagnosis with gonorrhea and/or 
chlamydia in the current pregnancy (OR 3.59, 95% CI 1.36–9.48, p=0.010), carriage of a 
male fetus (OR 1.51, 95% CI 1.02–2.24, p=0.040), and a penultimate pregnancy delivering 
preterm (OR 2.10, 95% CI 1.03–4.25, p=0.041) were associated with an increased likelihood 
of non-response to 17OHP-C (Table 5).
Next, we developed a prognostic scoring system for non-response to 17-OHPC using the 
results from the logistic regression model (Table 5). To create the risk scoring model, the 
IL-1β genotype factor variable was removed from the model in Table 5 as this is 
infrequently available clinically. Furthermore, the gestational age at the earliest prior PTB 
was converted to a dichotomous variable using cut-point calculations; it was determined that 
risk was highest at or beyond 32 weeks gestation. The scoring system model performed 
moderately well overall with an AUC of 0.73 +/− 0.02. The final risk prediction model is 
shown in Table 6. Each individual was then assigned a risk score based on this scoring 
system. For example, a Black woman (+1) carrying a female fetus (+0), with no gonorrhea 
or chlamydia (+0), a current diagnosis of abruption (+5), whose last and only other baby was 
delivered preterm (+2) at 29 weeks (+0) would have a total risk score of 8. Scores ranged 
from 0 to 18 in this cohort, with a median score of 6 (IQR 3, 8). Each additional point was 
found to increase the odds of non-response to 17OHP-C by 37% (OR 1.37, 95% CI 1.28–
1.48, p<0.001). When a cut-off of >6 was used to classify women at high risk for non-
response to 17OHP-C, the sensitivity of the risk score was 0.78 (95% CI 0.71–0.84) and the 
specificity 0.60 (95% CI 0.56–0.64), with an AUC of 0.69 (95% CI 0.65–0.73). The positive 
predictive value was 0.34 (95% CI 0.30–0.40), and the negative predictive value was 0.91 
(95% CI 0.88–0.94). Results were similar if only women with a penultimate PTB were 
considered (results not shown).
The scoring system was then validated using de-identified data from the Meis RCT of 
17OHP-C vs. placebo. The Meis study enrolled 463 women; two-thirds (310) were 
randomized to receive 17OHP-C, of these, 4 were excluded due to a missing 17OHP-C 
effect, and 19 were excluded because they were classified as equivocal 17OHP-C 
responders. Among the remaining 287 women in the validation set, 63 (22.0%) were non-
responders. In the validation set, scores ranged from 0 to 14, with a median score of 4 (IQR 
3, 8). Each additional point was found to increase the odds of non-response to 17OHP-C by 
32% (OR 1.32, 95% CI 1.19–1.47, p<0.001). When a cut-off of >6 was used to classify 
women at high risk for non-response to 17OHP-C, the sensitivity of the risk score was 0.65 
(95% CI 0.52–0.77) and the specificity 0.66 (95% CI 0.60–0.73), with an AUC of 0.66 (95% 
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CI 0.59–0.72). The positive predictive value was 0.35 (95% CI 0.27–0.45), and the negative 
predictive value was 0.87 (95% CI 0.81–0.92).
Finally, we performed a limited subgroup analysis examining the 31 women in the main 
cohort who delivered significantly earlier (≥3 weeks) with 17OHP-C compared to the 
gestational age of their earliest prior PTB, a potential ‘harm’ group (Figure 1). These 31 
women delivered at a mean 26.3 +/− 4.0 weeks gestation during the 17OHP-C treated 
pregnancy, compared to their previously earliest PTB, which occurred at a mean 32.4 +/
− 3.7 weeks gestation. A significantly higher proportion of women in the potential harm 
group, 20/31 (64.5%) were Black, compared to 33/128 (25.8%) of other non-responders and 
199/595 (33.5%) of responders, p<0.001. Compared to the other non-responders, women 
delivering significantly earlier were also more likely to be diagnosed with a short cervical 
length <2.50cm during pregnancy (3/14, 21.4% vs. 1/45, 2.2%, p=0.038), and had a trend 
towards even higher rates of placental abruption (19.4% vs. 9.4%, p=0.116). However, other 
characteristics were similar between women in the potential harm group compared to the 
other non-responders. Unfortunately, the small number of women in this subgroup precluded 
additional regression analyses.
Comment
We have identified several risk factors for non-response to 17OHP-C, including the 
gestational age of the previous earliest PTB, placental abruption in the current pregnancy, 
gonorrhea or chlamydia infection, and male fetus. Furthermore, Black race and maternal 
IL-1β+3954 genotype may also influence the likelihood of response to 17OHP-C. We have 
generated a preliminary risk scoring system for non-response to 17OHP-C using these 
findings. Unfortunately, response to 17OHP-C remains imperfect and further refinement is 
necessary before clinical application. These data add to a growing body of literature 
suggesting that women who experience a recurrent PTB or recurrent PTB at a similar 
gestational age while receiving 17OHP-C have distinctly different clinical and biologic 
characteristics than those who receive 17OHP-C and deliver at term.8,10,11,18
These results are consistent with and confirm our previous results from a separate cohort of 
women at high risk for recurrent SPTB.10 Our prior study included 155 women; 37 (24%) 
were classified as non-responders, which is similar to the 21% non-responder rate in the 
current study. In that study, we also identified the gestational age of the earliest previous 
spontaneous PTB, significant vaginal bleeding or abruption, first-degree family history of 
SPTB, and preterm birth of the penultimate pregnancy as risk factors for reduced response to 
17OHP-C.10 We have confirmed these results in the current study. We were unable to 
evaluate family history in the current report, as this information was not collected as part of 
the original RCT. The current study includes a substantially larger number of subjects than 
our previous report and therefore allows for additional power to detect other risk factors 
associated with 17OHP-C response, including fetal sex, Black race, and maternal genital 
tract infection with gonorrhea or chlamydia. The risk scoring system presents a simplified 
summary of results of the logistic regression, in a manner that is easy to clinically interpret.
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We found that women carrying male fetuses had an increased likelihood of non-response to 
17OHP-C. This extends previous observations that male sex increases the risk of preterm 
birth and is associated with worse neonatal outcomes.19,20 Black race is an established risk 
factor for SPTB, and multiple studies have demonstrated that Black women have earlier PTB 
and are more likely to have recurrent PTB.21 Although a similar proportion of Black women 
were responders and non-responders in bivariate analysis, Black race remained in final 
regression models predicting non-response, and confers one point in the risk score. 
Furthermore, a large proportion of women (20/31, or 64.5%) in the potential harm group 
were of Black race. Although Black women are known to be at higher risk for recurrent PTB 
compared to white women, the finding of earlier PTB with 17OHP-C is novel. Caution 
should be advised when drawing conclusions based on these data, however, given the small 
number of women in this subgroup.
This study is not without limitations. As with any secondary analysis, we were limited by 
the data collected during the original study. Unfortunately, we do not have information 
regarding family history of PTB, nor do we have detailed information regarding prior 
pregnancy phenotype (e.g., history of preterm premature rupture of membranes, or history of 
cervical insufficiency). Due to small numbers and population stratification issues, we were 
unable to examine the relationship between genotype and response. We do not have 
information regarding 17P exposure in previous pregnancies, though this is likely negligible 
as 70% of this population had only one previous PTB and the current gestation was their 
first 17P eligible pregnancy, and many others included here would have had pregnancies 
prior to the publication of the Meis trial in June 2003. Likewise, the small numbers of 
potential harm subjects also prevented us from performing a regression analysis in this 
subset of women. Additionally, the risk factors identified in the logistic regression model are 
all known risk factors for SPTB; given the design of the parent study, we are unable to 
conclude causality between 17OHP-C treatment and outcome.
This study also has several strengths. This is a very high-risk cohort; all subjects had at least 
one prior documented SPTB and 90% had a penultimate PTB. In contrast to the majority of 
studies of 17OHP-C, the injections in both the main analysis and validation set were a 
proscribed part of the study protocol and compliance carefully documented. All data were 
prospectively collected and the study was conducted across the United States at tertiary care 
centers representative of maternal-fetal medicine and obstetric care received by women at 
high risk for PTB. Further, we were able to consider limited genetic data with clinical factors 
to determine likelihood of response to 17OHP-C. Our definition of 17OHP-C response is 
clinically relevant, because at periviable gestational ages, pregnancy prolongation of even 3 
weeks increases the probability of neonatal survival from 7 to 77%.22,23
Although promising, additional refinement and further external validation is needed prior to 
clinical implementation of the risk-scoring model. With the addition of more patients and 
high-quality data, future studies should work to improve the AUC to better discriminate 
responders and non-responders. Although there are currently no alternate therapies to 
17OHP-C (in the setting of a high or positive risk score for non-response), the negative 
predictive value was high for both the test and validation cohorts, and may provide 
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reassurance to some women. This is an example of an easy to understand, simple clinical 
application of these data to real world patient care settings.
It should be emphasized that while these data are consistent with our previous findings10 and 
provide additional information and insight regarding the likelihood of response to 17OHP-C, 
they are insufficient to recommend changes in clinical practice. As described above, 
although the risk-scoring model may identify women at highest risk for non-response to 
17OHP-C, there are currently no acceptable alternative or adjunct therapies. At this time, we 
continue to recommend, in accordance with current SMFM and ACOG guidelines, that all 
women with a history of a prior singleton SPTB prior to 37 weeks gestation are offered 
weekly 17OHP-C beginning at 16–20 weeks.24,25 Future studies should incorporate clinical 
and genetic factors such as those reported here to identify individuals who may be the best 
candidates for alternative or additional therapies for SPTB prevention.
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Figure 1. Study enrollment
*Equivocal 17P responders: Earliest prior preterm birth was 35–36 weeks, delivered during 
early term period (37–38 weeks), see text for details
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Table 1
Demographic factors and prior pregnancy history by 17OHP-C responder status.
17OHP - C non-
responder
(n=159)
17OHP - C responder
(n=595)
P - value
Maternal age (mean, ± SD) 27.1 ± 5.8 27.9 ± 5.5 0.121
Maternal race, n (%)
0.001
 Black 53 (33.3) 199 (33.5)
 White 93 (58.5) 278 (46.7)
 Other 13 (8.2) 118 (19.8)
Maternal Hispanic ethnicity, n (%) 11 (6.9) 100 (16.8) 0.002
Gestational age of earliest prior spontaneous preterm birth (mean, ± SD) 32.3 ± 4.1 29.1 ± 4.5 <0.001
Penultimate pregnancy delivered preterm, n(%) 147 (92.5) 525 (88.2) 0.121
Number of prior spontaneous preterm births (mean, ± SD) 1.4 ± 0.6 1.4 ± 0.7 0.597
More than one prior spontaneous preterm birth, n (%) 55 (34.6) 169 (28.4) 0.129
One or more previous term birth(s), n(%) 46 (28.9) 210 (35.3) 0.132
Gestational age at randomization and initiation of 17OHP-C, weeks 
(mean, ± SD)
19.5 ± 1.7 19.3 ± 1.7 0.198
17OHP-C injection compliance, median % (IQR) 100 (92, 100) 100 (93, 100) 0.022
Abbreviations = 17OHP-C: 17-alpha hydroxyprogesterone caproate; IQR: interquartile range (25th and 75th percentiles)
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Table 2
Current pregnancy factors by 17OHP-C responder status.
17OHP - C non-
responder
(n=159)
17OHP - C responder
(n=595)
P - value
Pre-pregnancy body mass index (kg/m2), mean +/− SD 26.0 +/− 6.6 26.7 +/− 6.7 0.284
Smoked during pregnancy, n (%) 26 (16.4) 94 (15.8) 0.865
One or more episode(s) of vaginal bleeding or diagnosis of clinical 
abruption, n (%)
18 (11.3) 19 (3.2) <0.001
Bacterial vaginosis, n(%) 11 (23.4) 43 (33.1) 0.217
Trichomonas during pregnancy, n(%) 2 (4.3) 14 (10.8) 0.182
Gonorrhea and/or chlamydia infection during pregnancy, n(%) 11 (6.9) 13 (2.2) 0.003
Short cervix <2.50cm*, n (%) 4 (6.8) 9 (3.0) 0.243
Cervical cerclage, n(%) 4 (2.5) 12 (2.0) 0.698
Randomized to receive omega3 capsules, n(%) 81 (50.9) 301 (50.6) 0.937
Received antenatal corticosteroids, n(%) 43 (27.0) 110 (18.5) 0.017
Received tocolysis, n(%) 52 (32.7) 107 (18.0) <0.001
Median number of hospital admissions for tocolysis (IQR) 0 (0, 1) 0 (0, 0) <0.001
Male fetus 92 (57.9) 285 (47.9) 0.026
*
among 355 women with at least one transvaginal cervical length assessment
Abbreviations = 17OHP-C: 17-alpha hydroxyprogesterone caproate; IQR: interquartile range (25th and 75th percentiles)
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Table 3








 CC* 1 (2.0) 0 (0.0)
 GC 9 (18.0) 44 (22.2)
 GG 40 (80.0) 154 (77.8)
TNFα-308*, n (%)
0.361
 AA* 1 (2.0) 4 (2.0)
 AG 7 (14.0) 46 (23.2)
 GG 42 (84.0) 148 (74.8)
IL-1β+3954*, n (%)
0.062
 TT* 3 (6.0) 3 (1.5)
 CT 7 (14.0) 49 (24.8)




Genotype data available for 248/252 (98%) of Black women.
Abbreviations = 17OHP-C: 17-alpha hydroxyprogesterone caproate
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Table 4








 CC* 14 (13.6) 48 (13.1)
 GC 47 (46.6) 169 (46.2)
 GG 42 (40.8) 149 (40.7)
TNFα-308*, n (%)
0.157
 AA* 4 (3.9) 4 (1.1)
 AG 27 (26.2) 95 (26.2)
 GG 72 (69.9) 264 (72.7)
IL-1β+3954*, n (%)
0.051
 TT* 8 (7.8) 16 (4.4)
 CT 41 (39.8) 112 (30.6)




Genotype data available for 466/482 (97%) of White and Hispanic/non-Black women
Abbreviations = 17OHP-C: 17-alpha hydroxyprogesterone caproate
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Table 5
Multivariable logistic regression model. Shown are factors associated with non-response to 17OHP-C.
Characteristic OR 95% CI p-value
Gestational age of earliest prior preterm birth (each additional week) 1.23 1.17–1.30 <0.001
Placental abruption or significant vaginal bleeding in the current pregnancy 5.60 2.46–12.71 <0.001
Gonorrhea and/or chlamydia in the current pregnancy 3.59 1.36–9.48 0.010
Male fetus 1.51 1.02–2.24 0.040
Penultimate pregnancy delivered preterm 2.10 1.03–4.25 0.041
Maternal Interleukin-1 beta genotype (per each copy of the minor allele) 1.31 0.94–1.82 0.114
Black race 1.37 0.88–2.15 0.165
*
Additional factors considered in model included: randomization group, maternal tumor necrosis factor alpha genotype, maternal interleukin 6 
genotype; these were removed from the final model due to p>0.20.
Abbreviations = 17OHP-C: 17-alpha hydroxyprogesterone caproate
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Table 6




Last pregnancy delivered preterm +2
Gonorrhea and/or chlamydia in the current pregnancy +4
Placental abruption or significant vaginal bleeding in the current pregnancy +5
Earliest prior preterm birth was 32 – 36 weeks gestation +5
SUM to get score Possible range = 0 to 18
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